922 1030
[(Fig._1)TD$FIG]
Private practice
Östersund
Örnsköldsvik
Umeå
Sundsvall
Skellefteå
Lycksele
Boden
Varberg
Uddevalla
Trollhättan
Skövde
Skene
Mölndal
Lidköping
Kungälv
Göteborg
Borås
Alingsås
Ängelholm
Ystad
Växjö
Trelleborg
Malmö
Lund
Kristianstad
Karlskrona
Karlshamn
Hässleholm
Helsingsborg
Halmstad
Västervik
Värnamo
Oskarshamn
Norrköping
Motala
Linköping
Kalmar
Jönköping
Eksjö
Örebro
Västerås
Uppsala
Säffle
Nyköping
Mora
Karlstad
Karlskoga
Hudiksvall
Gävle
Falun
Eskilstuna
Enköping
Arvika
Visby
Stockholm − Södermalm
Stockholm − Solna
Stockholm − Huddinge
Stockholm − Danderyd
1992−1993
1994−1995
1996−1997
1998−1999
Healthcare provider
0
100
Percent GnRH agonists
Fig. 1 – Percentage of men who received gonadotropin-releasing hormone (GnRH) agonists as primary
[7_TD$DIFF]
treatment (ADT) by healthcare provider and time
period in Prostate Cancer
[8_TD$DIFF]
data Base
[9_TD$DIFF]
Sweden (PCBaSe) 3.0. Men diagnosed by healthcare provider with <15 cases of primary
[10_TD$DIFF]
androgen deprivation
therapy per year during the specific time period were excluded (red rectangles). The National Prostate Cancer Register captured men diagnosed with
prostate cancer in the Northern region from 1992, the Southeastern region from 1994, the Western, Southern, and Uppsala O¨ rebro regions from 1996,
and the Stockholm region from 1998.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 2 0 – 9 2 8
922